Patent · US Active

Engineered chimeric fusion protein compositions and methods of use thereof

US11628218B2 · kind B2 · utility

3Cited by

40References

22Claims

0Family size

Assignee

MYELOID THERAPEUTICS, INC. · US

Inventors

Daniel R. Getts · Evanston, US
Yuxiao Wang · Belmont, US
Bruce McCreedy · Raleigh, US

Key dates

Filing date	Feb 1, 2022
Grant date	Apr 18, 2023
Priority date	—
Expiry date	Feb 1, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.